For example, it is unknown whether CDK4/6 inhibitors such as palbociclib or abemaciclib can be employed for RB1‐proficient GBM or if CDKN2A/B and CDK4/6 status also need to be considered [116]. This evidence concerns the gene CDKN2A and glioblastoma.